108 related articles for article (PubMed ID: 1351724)
1. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
Slomiany BL; Piotrowski J; Murty VL; Slomiany A
Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
[TBL] [Abstract][Full Text] [Related]
3. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
4. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
5. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
6. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
7. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
8. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
9. Effect of ebrotidine on gastric mucosal calcium channel activity.
Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
[TBL] [Abstract][Full Text] [Related]
10. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
[TBL] [Abstract][Full Text] [Related]
11. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
12. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression.
Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1993 Aug; 30(6):1127-34. PubMed ID: 8106073
[TBL] [Abstract][Full Text] [Related]
13. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.
Slomiany BL; Lopez RA; Slomiany A
Biochem Int; 1992 Dec; 28(4):665-74. PubMed ID: 1482403
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.
Slomiany BL; Piotrowski E; Piotrowski J; Zirvi KA; Liau YH; Murty VL; Slomiany A
Gen Pharmacol; 1994 Sep; 25(5):1033-7. PubMed ID: 7835621
[TBL] [Abstract][Full Text] [Related]
16. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
17. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
[TBL] [Abstract][Full Text] [Related]
18. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[TBL] [Abstract][Full Text] [Related]
19. Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication.
Slomiany BL; Piotrowski J; Slomiany A; Konturek JW; Domschke WW
Gen Pharmacol; 1998 Aug; 31(2):227-31. PubMed ID: 9688464
[TBL] [Abstract][Full Text] [Related]
20. Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans.
Konturek SJ; Kwiecien N; Sito E; Obtulowicz W; Kaminski K; Oleksy J
Scand J Gastroenterol; 1993 Dec; 28(12):1047-50. PubMed ID: 7905660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]